Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 June 2018Website:
http://www.meiragtx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:09:07 GMTDividend
Analysts recommendations
Institutional Ownership
MGTX Latest News
MeiraGTx (MGTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.
The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MeiraGTx Holdings PLC (NASDAQ:MGTX) shares gained more than 25% after it announced Sanofi SA (ADR) (NYSE:SNY), a pharma giant best known for its vaccines, is purchasing 4 million of the gene company's shares at a price of $7.50 per share for a total $30 million investment. MeiraGTx stock was up 25.4% at US$4.64 late morning on Monday, while Sanofi shares gained 3.5% at US$44.63.
Shares of MeiraGTx Holdings PLC MGTX, -4.88% jumped 14% premarket on Monday after the gene therapy company announced that French drugmaker Sanofi SNY, -19.13% has made a $30 million investment.
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.76 per share a year ago.
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The consensus price target hints at a 320.9% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What type of business is MeiraGTx Holdings?
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
What sector is MeiraGTx Holdings in?
MeiraGTx Holdings is in the Healthcare sector
What industry is MeiraGTx Holdings in?
MeiraGTx Holdings is in the Biotechnology industry
What country is MeiraGTx Holdings from?
MeiraGTx Holdings is headquartered in United States
When did MeiraGTx Holdings go public?
MeiraGTx Holdings initial public offering (IPO) was on 08 June 2018
What is MeiraGTx Holdings website?
https://www.meiragtx.com
Is MeiraGTx Holdings in the S&P 500?
No, MeiraGTx Holdings is not included in the S&P 500 index
Is MeiraGTx Holdings in the NASDAQ 100?
No, MeiraGTx Holdings is not included in the NASDAQ 100 index
Is MeiraGTx Holdings in the Dow Jones?
No, MeiraGTx Holdings is not included in the Dow Jones index
When does MeiraGTx Holdings report earnings?
The next expected earnings date for MeiraGTx Holdings is 09 August 2024